Abstract
Background Family history (FHx) of cardiovascular disease (CVD) is a risk factor for CVD and a proxy for cardiovascular heritability. Polygenic risk scores (PRS) summarizing >1 million variants for coronary artery disease (CAD) are associated with incident and recurrent CAD events. However, little is known about the influence of FHx or PRS on secondary cardiovascular events (sCVE) in patients undergoing carotid endarterectomy (CEA).
Methods We included 1,788 CEA patients from the Athero-Express Biobank. A weighted PRS for CAD including 1.7 million variants was calculated (MetaGRS). The composite endpoint of sCVE during three years follow-up included coronary, cerebrovascular and peripheral events and cardiovascular death. We assessed the impact of FHx and MetaGRS on sCVE and carotid plaque composition.
Results Positive FHx was associated with a higher 3-year risk of sCVE independent of cardiovascular risk factors and MetaGRS (adjusted HR 1.40, 95%CI 1.07-1.82, p=0.013). Patients in the highest MetaGRS quintile had a higher 3-year risk of sCVE compared to the rest of the cohort independent of cardiovascular risk factors including FHx (adjusted HR 1.35, 95%CI 1.01-1.79, p=0.043), and their atherosclerotic plaques contained more fat (adjusted OR 1.59, 95%CI, 1.11-2.29, p=0.013) and more macrophages (OR 1.49, 95%CI 1.12-1.99, p=0.006).
Conclusion In CEA patients, both positive FHx and higher MetaGRS were independently associated with increased risk of sCVE. Moreover, higher MetaGRS was associated with vulnerable plaque characteristics. Future studies should unravel underlying mechanisms and focus on the added value of PRS and FHx in individual risk prediction for sCVE.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. van der Laan was funded through grants from the Netherlands CardioVascular Research Initiative of the Netherlands Heart Foundation (CVON 2011/B019 and CVON 2017-20: Generating the best evidence-based pharmaceutical targets for atherosclerosis [GENIUS I&II]). Dr. Timmerman, Dr. De Borst, dr. De Kleijn, and dr. Pasterkamp are funded through the EU 755320 Taxinomisis grant. We acknowledge the European Research Area Network on Cardiovascular diseases (ERA-CVD, grant number 01KL1802). There are no competing interests declared.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
↵* These authors jointly supervised this project.
Declarations of interest: none
Financial support, Dr. van der Laan was funded through grants from the Netherlands CardioVascular Research Initiative of the Netherlands Heart Foundation (CVON 2011/B019 and CVON 2017-20: Generating the best evidencebased pharmaceutical targets for atherosclerosis [GENIUS I&II]). Dr. Timmerman, Dr. De Borst, dr. De Kleijn, and dr. Pasterkamp are funded through the EU 755320 Taxinomisis grant. We acknowledge the European Research Area Network on Cardiovascular diseases (ERA-CVD, grant number 01KL1802). There are no competing interests declared.
Data Availability
Data will be available upon request.
Abbreviations
- PRS
- polygenic risk score
- CVD
- cardiovascular disease
- CAD
- coronary artery disease
- SNP
- single-nucleotide polymorphism
- FHx
- family history of premature CVD
- MetaGRS
- polygenic risk score for CAD including 1.7 million SNPs associated with CAD CEA carotid endarterectomy
- CVE
- cardiovascular event
- sCVE
- secondary cardiovascular event MI myocardial infarction
- AAA
- abdominal aortic aneurysm
- ACS
- acute coronary syndrome defined as a composite of myocardial infarction and unstable angina pectoris
- PAD
- peripheral artery disease
- GWAS
- large-scale genome wide association studies
